BTS 74,398

In today's world, BTS 74,398 has acquired unprecedented relevance. Known for its impact on various aspects of society, BTS 74,398 has captured the attention of academics, experts and the general public. Its influence extends to areas such as economics, politics, technology, culture and everyday life. As BTS 74,398 continues to be the subject of analysis and debate, it is crucial to understand its implications and consequences now and in the future. In this article, we will explore in detail the importance and scope of BTS 74,398, as well as its possible effects on society.

BTS 74,398
Identifiers
  • 1-(-2-(3-diaminethylaminopropylthio)ethanone
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H29Cl2N3OS
Molar mass418.42 g·mol−1
3D model (JSmol)
  • NCCN(CCN)CCCSCC(=O)C2(CCC2)c(cc1Cl)ccc1Cl

  • c1cc(c(cc1C2(CCC2)C(=O)CSCCCN(CCN)CCN)Cl)Cl
  • InChI=1S/C19H29Cl2N3OS/c20-16-4-3-15(13-17(16)21)19(5-1-6-19)18(25)14-26-12-2-9-24(10-7-22)11-8-23/h3-4,13H,1-2,5-12,14,22-23H2 checkY
  • Key:OLQJWCYRPYGTJI-UHFFFAOYSA-N checkY
  (verify)

BTS 74,398 is a centrally acting stimulant drug which was developed for the treatment of Parkinson's disease. It inhibits the synaptic reuptake of dopamine, serotonin and noradrenaline, making it a triple reuptake inhibitor.[1] It was effective in animal models of Parkinson's disease,[2][3] but was unsuccessful in human trials.[4]

References

  1. ^ Lane EL, Cheetham S, Jenner P (March 2005). "Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors". The Journal of Pharmacology and Experimental Therapeutics. 312 (3): 1124–31. doi:10.1124/jpet.104.076554. PMID 15542624. S2CID 8208352.
  2. ^ Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P (January 2004). "The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates". Movement Disorders. 19 (1): 15–21. doi:10.1002/mds.10596. PMID 14743355. S2CID 26120965.
  3. ^ Lane EL, Cheetham SC, Jenner P (January 2005). "Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours". The European Journal of Neuroscience. 21 (1): 179–86. doi:10.1111/j.1460-9568.2004.03834.x. PMID 15654855. S2CID 22417785.
  4. ^ Lane EL, Cheetham S, Jenner P (2008). "Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398". Journal of Neural Transmission. 115 (3): 423–9. doi:10.1007/s00702-007-0854-x. PMID 18250952. S2CID 195993.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about an amine is a stub. You can help Wikipedia by expanding it.